Valuation: Inventiva

Market Cap 913M 1.04B 848M 780M 1.46B 101B 1.49B 10.14B 3.96B 49.05B 3.9B 3.81B 170B P/E 2026 *
-5.29x
P/E 2027 * -4.94x
Enterprise Value 746M 848M 693M 637M 1.19B 82.11B 1.22B 8.28B 3.23B 40.05B 3.18B 3.11B 139B EV / Sales 2026 *
111x
EV / Sales 2027 * 2.81x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day-0.26%
1 week+1.05%
Current month+20.03%
1 month+21.73%
3 months-14.11%
6 months-35.37%
Current year-2.03%
1 week 3.72
Extreme 3.72
4.08
1 month 2.88
Extreme 2.88
4.08
Current year 2.88
Extreme 2.88
6.2
1 year 2.71
Extreme 2.71
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 75 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

Head of Human Resources

25,000 0.0131%
1/10/26 Others

Chief Operating Officer

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+1.05%+40.04%+5.46% 1.04B
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-1.27%+4.71%+29.72%-4.51% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-1.15%+5.78%+32.67%+544.74% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.27%+1.24%+41.94%+153.05% 24.3B
Weighted average by Cap. +1.25%+3.17%+43.39%+133.40%

Financials

2026 *2027 *
Net sales 6.73M 7.65M 6.25M 5.75M 10.79M 741M 10.98M 74.79M 29.17M 362M 28.74M 28.12M 1.25B 109M 123M 101M 92.76M 174M 11.95B 177M 1.21B 470M 5.83B 463M 453M 20.23B
Net income -150M -170M -139M -128M -240M -16.47B -244M -1.66B -648M -8.03B -639M -625M -27.88B -102M -116M -95.12M -87.49M -164M -11.27B -167M -1.14B -444M -5.5B -437M -428M -19.08B
Net Debt -168M -190M -156M -143M -268M -18.44B -273M -1.86B -726M -9B -715M -700M -31.21B -608M -691M -565M -519M -974M -66.93B -991M -6.75B -2.63B -32.65B -2.59B -2.54B -113B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-07-23 €3.865 -0.26% 243,515
26-07-22 €3.875 -1.02% 296,293
26-07-21 €3.915 +1.42% 211,745
26-07-20 €3.860 -3.26% 342,802
26-07-17 €3.990 +4.31% 440,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.865EUR
Average target price
9.634EUR
Spread / Average Target
+149.27%

Quarterly revenue - Rate of surprise